Published in J Clin Invest on February 06, 2017
TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors | NCT04969315
Targeting A2 adenosine receptors in cancer. Immunol Cell Biol (2017) 0.75
Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer (2017) 0.75
Driving better and safer HER2-specific CARs for cancer therapy. Oncotarget (2017) 0.75
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 5.23
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med (2016) 4.33
A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther (2009) 2.52
Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol (2006) 2.37
A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol (2005) 2.37
Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol (2000) 2.25
CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 2.13
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol (2015) 2.11
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell (2016) 2.00
Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol (1998) 1.96
Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci Signal (2009) 1.85
Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res (2008) 1.84
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol (2014) 1.53
CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 1.52
Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo. Leukemia (2015) 1.45
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med (2014) 1.44
High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma. Tumour Biol (2015) 1.42
Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med (2015) 1.42
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 1.40
Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res (2013) 1.36
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A (2013) 1.32
Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med (2016) 1.24
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol (2004) 1.24
The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol (2012) 1.18
Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol (1999) 1.16
Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol (1997) 1.16
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother (2011) 1.16
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A (2005) 1.14
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood (2005) 1.10
Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol (2001) 1.07
Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res (2014) 1.06
Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res (2010) 1.04
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res (2014) 1.01
The roles of CD73 in cancer. Biomed Res Int (2014) 1.01
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunol Res (2015) 1.01
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J (2015) 1.00
CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancer Res (2015) 1.00
Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res (2014) 0.99
Packaging shRNA retroviruses. Cold Spring Harb Protoc (2013) 0.98
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res (2016) 0.96
Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res (2014) 0.96
Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol (2000) 0.94
CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. Clin Cancer Res (2015) 0.91
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun (2016) 0.87
Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol (2016) 0.83
Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Model Mech (2015) 0.83
Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor. Cancer Immunol Immunother (1993) 0.82
Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. Immunotherapy (2015) 0.80
Ecto-5'-nucleotidase expression is associated with the progression of renal cell carcinoma. Oncol Lett (2015) 0.78
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol (2016) 0.78
Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Semin Immunol (2015) 0.78
CD73: A potential biomarker for anti-PD-1 therapy. Oncoimmunology (2015) 0.77
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell (2011) 7.02
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med (2015) 6.38
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol (2008) 4.13
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.66
A common fold mediates vertebrate defense and bacterial attack. Science (2007) 3.43
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell (2007) 3.13
Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol (2006) 3.04
A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity (2005) 2.97
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol (2006) 2.84
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 2.64
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor. Immunity (2012) 2.58
The HIN-200 family: more than interferon-inducible genes? Exp Cell Res (2005) 2.53
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol (2012) 2.50
Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther (2009) 2.50
Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J Immunol (2007) 2.43
Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood (2005) 2.39
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst (2012) 2.34
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell (2012) 2.29
Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity (2012) 2.23
The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature (2010) 2.23
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
The MACPF/CDC family of pore-forming toxins. Cell Microbiol (2008) 2.15
Rational combinations using HDAC inhibitors. Clin Cancer Res (2009) 2.12
Cytokines in cancer immunity and immunotherapy. Immunol Rev (2004) 2.09
Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood (2012) 2.07
IFNgamma signaling-does it mean JAK-STAT? Cytokine Growth Factor Rev (2008) 2.06
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett (2009) 1.99
The molecular basis for perforin oligomerization and transmembrane pore assembly. Immunity (2009) 1.98
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res (2008) 1.94
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood (2002) 1.83
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest (2012) 1.79
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res (2012) 1.77
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res (2003) 1.73
Protection from endogenous perforin: glycans and the C terminus regulate exocytic trafficking in cytotoxic lymphocytes. Immunity (2011) 1.73
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev (2013) 1.73
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol (2001) 1.70
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood (2011) 1.69
Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs (2007) 1.60
Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res (2012) 1.59
Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol (2010) 1.58
Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res (2012) 1.55
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. Blood (2013) 1.53
CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 1.52
Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol (2002) 1.50
AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. Sci Signal (2011) 1.49
The major human and mouse granzymes are structurally and functionally divergent. J Cell Biol (2006) 1.48
Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene (2005) 1.47
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol (2009) 1.47
Asymmetric cell division of T cells upon antigen presentation uses multiple conserved mechanisms. J Immunol (2010) 1.46
Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One (2008) 1.42
Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol (2007) 1.41
Functional crosstalk between type I and II interferon through the regulated expression of STAT1. PLoS Biol (2010) 1.40
Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity (2002) 1.39
Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem (2005) 1.39
CD73-deficient mice are resistant to carcinogenesis. Cancer Res (2012) 1.38
Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res (2012) 1.36
Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res (2013) 1.36
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther (2013) 1.33
Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. BMC Bioinformatics (2010) 1.33
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A (2008) 1.33
Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2. Biochem Biophys Res Commun (2005) 1.32